Stockreport

Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 [Yahoo! Finance]

Kyverna Therapeutics, Inc.  (KYTX) 
PDF KYV-101 Treatment Continues to Demonstrate Robust Safety and Tolerability With No High-Grade CRS or ICANS Observed EMERYVILLE, Calif. Nov. 14, 2024 /PRNewswire/ -- Ky [Read more]